-
Frank accepts 'boring' jibes from Spurs fans after Brentford stalemate
-
Guardiola vexed by Man City's sloppy finishing in Sunderland draw
-
Tears and stunned silence at vigil for Swiss fire victims
-
Wembanyama to miss Spurs' NBA game Friday at Indiana: reports
-
Man City charge stalls at Sunderland, Liverpool held by Leeds
-
Man City's title bid dented by Sunderland stalemate
-
Australia's Khawaja announces retirement from international cricket
-
Niners seek win for home-field playoff edge into Super Bowl
-
New York mayor Mamdani pledges left-wing success after taking office
-
Slot frustrated by blunt Liverpool in Leeds stalemate
-
Toothless Liverpool held by Leeds
-
Dozens killed as fire ravages Swiss ski resort New Year party
-
K-pop stars BTS to release album in March ahead of world tour
-
Fresh clashes kill six in Iran cost-of-living protests
-
Nigeria kicks off new tax regime vowing relief for low earners
-
Dozens killed in fire at Swiss ski resort New Year party
-
Leftist Mamdani begins first day as New York mayor
-
Dozens believed killed in fire at Swiss ski resort New Year party
-
Brazil Supreme Court rejects Bolsonaro request for house arrest on health concerns
-
Israel confirms ban on 37 NGOs in Gaza
-
Russia blames Ukraine for deadly New Year drone strike
-
Coach Maresca leaves Chelsea - club
-
'Several dozen' believed killed in fire at Swiss ski resort New Year party
-
China's BYD logs record EV sales in 2025
-
Yemen separatists say Saudi-backed forces to deploy in seized territories
-
Wales rugby star Rees-Zammit signs long-term deal to stay at Bristol
-
'Several dozen' believed killed in fire at Swiss ski resort New Year bash
-
Hakimi, Salah and Osimhen head star-packed AFCON last-16 cast
-
Israel says it 'will enforce' ban on 37 NGOs in Gaza
-
Near record number of small boat migrants reach UK in 2025
-
Several dead as fire ravages bar in Swiss ski resort town Crans Montana: police
-
Tsitsipas considered quitting tennis during injury-hit 2025
-
Sabalenka wants 'Battle of the Sexes' rematch and revenge
-
Osaka drawing inspiration from family at United Cup
-
Leftist Mamdani takes over as New York mayor under Trump shadow
-
Israel's Netanyahu among partygoers at Trump's New Year's Eve fete
-
Champagnie, Wemby lead Spurs comeback in Knicks thriller
-
Eight dead in US strikes on alleged drug boats: US military
-
Trump joins criticism of Clooney's French passport
-
AI, chips boom sent South Korea exports soaring in 2025
-
Taiwan's president vows to defend sovereignty after China drills
-
N. Korea's Kim hails 'invincible alliance' with Russia in New Year's letter
-
In Venezuela, price of US dollar up 479 percent in a year
-
Cummins, Hazlewood in spin-heavy Australia squad for T20 World Cup
-
Ex-boxing champ Joshua discharged from hospital after fatal car crash
-
Kamenar to Open for Tom Hamilton of Aerosmith's New Band Close Enemies at the World-Famous Whisky a Go Go - January 3, 2026
-
SUPCASE Unveils Its 2026 Brand Evolution: Lighter in Form, Stronger in Purpose
-
The EPOMAKER RT82: Where Retro Meets Modern Technology
-
Zelensky says deal to end war '10 percent' away
-
Trump bashes Clooney after actor becomes French
| SCS | 0.12% | 16.14 | $ | |
| CMSD | 0.09% | 23.15 | $ | |
| NGG | -0.54% | 77.35 | $ | |
| BCE | 1.05% | 23.82 | $ | |
| AZN | -0.63% | 91.93 | $ | |
| CMSC | -0.15% | 22.65 | $ | |
| GSK | -0.53% | 49.04 | $ | |
| RBGPF | -0.37% | 80.75 | $ | |
| BCC | -0.26% | 73.6 | $ | |
| RIO | -0.61% | 80.03 | $ | |
| RELX | -1.71% | 40.42 | $ | |
| JRI | 0.22% | 13.61 | $ | |
| RYCEF | 0.13% | 15.51 | $ | |
| VOD | -0.15% | 13.21 | $ | |
| BP | -0.06% | 34.73 | $ | |
| BTI | 0.12% | 56.62 | $ |
Verseon Chooses DataKrypto's FHEnom for AI(TM) to Ensure Continuous Encryption of AI-Driven Medical Research and Clinical Trial Data
News Summary:
Verseon International Corporation's mission is to drive groundbreaking scientific advances and transform modern medicine through physics- and AI-driven drug design, development, and clinical trials.
Verseon utilizes AI to accelerate and enhance innovation by analyzing sensitive clinical trial and patient data. To maintain compliance and uphold strict data privacy standards, Verseon must ensure data is protected at all times.
DataKrypto's new FHEnom for AI™ combines its revolutionary fully homomorphic encryption (FHE) with Trusted Execution Environments (TEEs) to deliver unprecedented data security for proprietary datasets.
The unique capabilities of the DataKrypto solution safeguard against malicious activities, misuse, and adversarial manipulation, fostering trust and dependability in AI-generated outcomes.
News Summary:
Verseon International Corporation's mission is to drive groundbreaking scientific advances and transform modern medicine through physics- and AI-driven drug design, development, and clinical trials.
Verseon utilizes AI to accelerate and enhance innovation by analyzing sensitive clinical trial and patient data. To maintain compliance and uphold strict data privacy standards, Verseon must ensure data is protected at all times.
DataKrypto's new FHEnom for AI™ combines its revolutionary fully homomorphic encryption (FHE) with Trusted Execution Environments (TEEs) to deliver unprecedented data security for proprietary datasets.
The unique capabilities of the DataKrypto solution safeguard against malicious activities, misuse, and adversarial manipulation, fostering trust and dependability in AI-generated outcomes.
BURLINGAME, CA / ACCESS Newswire / October 1, 2025 / DataKrypto, the creator of the fastest fully homomorphic encryption (FHE) solutions on the market, announced today that Verseon, a drug development innovator, is deploying its cutting-edge FHEnom for AI to ensure the continuous security of AI datasets and proprietary models.
Verseon's team of scientists, biologists, and medical researchers works diligently to create medicines that improve the world's treatment of all major human diseases. AI plays a vital role in Verseon's drug development and clinical trials, and ensuring that highly sensitive data is always protected, throughout AI training and inference, is crucial for maintaining compliance with stringent data privacy regulations.

"DataKrypto's FHEnom for AI gives us a secure, continuously encrypted solution for our AI training, fine-tuning, and real-world usage," said David Kita, CSO of Verseon. "With implementation taking just hours, the solution combines security with convenience and speed, allowing us to focus on our core activities."
"Verseon's mission-critical drug discovery and development work is reliant on its ability to maintain continuous protection of its clinical trial data and proprietary AI models," said Ravi Srivatsav, CEO of DataKrypto. "FHEnom for AI fills the encryption gap by enabling AI training and processing without having to decrypt data, which potentially exposes it to malicious use. We are proud to provide the first solution that gives companies like Verseon confidence and peace of mind with their AI implementations, knowing that their data is always secure."
Building Trust in AI with DataKrypto
FHEnom for AI is an AI-compliant, zero-knowledge framework that safeguards both customized open-source AI models (adapted for specific enterprise needs) and proprietary models, while ensuring the privacy and protection of sensitive data. It defends against malicious activities, misuse, and adversarial manipulation, securing intellectual property and maintaining the confidentiality of critical datasets. DataKrypto's solution helps companies deploying AI overcome concerns about data privacy and model security.
For more information about FHEnom for AI, visit https://datakrypto.com/products/.
About Verseon
Verseon International Corporation (www.verseon.com) is transforming the delay, prevention, and treatment of disease. Using its Deep Quantum Modeling + AI platform, Verseon is rolling out a steady stream of life-changing medicines. Each of the company's drug programs features multiple novel candidates with unique therapeutic properties. Other current methods can find none of these candidates. Verseon's rapidly growing pipeline addresses major human diseases in the areas of cardiometabolic disorders and cancer. The company's supporters and advisors include multiple Nobel laureates, former heads of R&D at major pharmaceutical companies, and various key opinion leaders in the field of medicine.
About DataKrypto
DataKrypto reimagines AI security for the enterprise. By combining FHEnom™-the fastest, most scalable Fully Homomorphic Encryption technology available-with Trusted Execution Environments (TEEs), DataKrypto enables organizations to adopt, create, and use AI tools with unmatched security and performance. Every model, every dataset-always encrypted. Even the largest AI systems run securely, with performance intact. DataKrypto empowers organizations to embrace AI, ensuring protection at every step. Learn more at www.datakrypto.com.
Media Contact:
Liz Youngs
Trier and Company for DataKrypto
1-843-412-6327
[email protected]
SOURCE: DataKrypto
View the original press release on ACCESS Newswire
L.Harper--AMWN